Post by: Colleen Parr Dekker
- Fourth Quarter 2022 Financial Results:
- Revenue of $988 million
- Reported Net Loss of $54 million, Adjusted Net Income of $95 million
- Adjusted EBITDA of $174 million or 17.6% of Revenue
- Reported EPS of $(0.11), Adjusted EPS of $0.19
- Net leverage ratio of 5.4x Adjusted EBITDA
- Full Year 2023 Guidance:
- Revenue of $4,280 to $4,400 million
- Reported Net Loss of $(157) to $(109) million, Adjusted EBITDA of $920 to $1,000 million
- Reported EPS of $(0.32) to $(0.22), Adjusted EPS of $0.74 to $0.83
- Initiated submission for JAK Inhibitor to the U.S. FDA with path to approval by first half of 2024; Received U.S. FDA approval of Bexacat, the first SGLT-2 inhibitor for feline diabetes, and U.S. EPA approval for the re-launch of two OTC parasiticides, Advantage for cats and K9 Advantix for dogs –new offerings in value segments.
- Updating expectations for U.S. approval and launch of Bovaer, a methane-reducing feed ingredient for cattle with blockbuster potential, by the first half of 2024.
GREENFIELD, IN (February 21, 2023) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2022, and provided initial guidance both for the first half and full year 2023.
